Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: J Gastrointest Surg. 2020 Nov 9;25(7):1828–1836. doi: 10.1007/s11605-020-04843-9

Figure 1: Response to Neo-IM in 150 primary GISTs.

Figure 1:

(a) Flowchart showing 1,000 GISTs treated surgically at a single institution[25], of which 150 had primary tumors and underwent treatment with neoadjuvant imatinib (Neo-IM). Note that only patients with complete data for response evaluation (n=125) were analyzed for survival in subsequent figures. (b) Response to Neo-IM in 150 patients by mRECIST (top), tumor viability (middle), and mitotic rate after resection (bottom). ‘x’ indicates no evaluable data for that factor. For mRECIST, viability, and mitotic rate there were 12, 17, and 26 unknown, respectively. Matched vertical lines in each graph represent the same patient.